- Institut Pasteur
- Support us
The Institut Pasteur is currently offering 10 major opportunities available for licensing in the fields of diagnostics, therapeutic, vaccines, imaging and enabling technologies.
Inventors: Pierre Lafaye
Invention Disclosure: 2007-067 and 2010-032
Key words: camelid single-domain antibodies (VHH), blood-brain barrier, intracellular carrier, neuro-diagnostic imaging, therapeutic use for brain disorders
This technology relates to the use of camelid heavy-chain antibodies (VHH domains) for delivering therapeutic or diagnostic agents across the mammal blood-brain barrier (BBB) and cell membranes.
In particular, we observed that VHHs, conjugated with GFP, were able to pass the BBB, enter into astrocytes and specifically bind to GFAP (Glial Fibrillary Acidic Protein) which is one of the major markers of astrocytes, as well as a crucial marker of gliosis in CNS tumors and degenerative conditions of brain tissues.
These antibodies therefore represent potential neuro-diagnostic imaging agents for brain diseases and therapeutic agents for brain disorders.
More generally, we are also interested in industrial collaborations to develop other pharmaceutical and biotechnological applications from the VHH technology.
Inventors: Pierre Bruhns
Invention Disclosure: 2010-036 and 2010-037 and 2012-046
Key words:Therapeutics antibodies, Human Fc receptors, Autoimmunity, Inflammation, Anaphylaxis
Multiple roles for mFcγRs (IgG receptors) have been reported in vivo without significant results for therapeutics application. New proof of mechanism evidence that expression of hFcγRI or hFcγRIIA was sufficient to induce models of autoimmune arthritis and thrombocytopenia, of immune complex-induced airway inflammation, of active and passive systemic anaphylaxis (allergic shock). Two monoclonal antibodies have been identified, that could block the binding of pathogenic antibodies to hFcγRI or hFcγRIIA. Results unravel two novel therapeutic antibodies that, when used in combination, should prevent the appearance of autoimmune, inflammatory and allergic diseases that rely on pathogenic antibodies, or reduce symptoms when administered after disease outbreak.
Inventors: Lucie Peduto
Invention Disclosure: 2009-028
Key words: early inflammation, ADAM12, metalloprotease, stromal cell, specific expression, therapeutic targed
Researchers observed 1) specific expression of ADAM12 (a disintegrin and metalloprotease 12) in injury-activated profibrotic progenitor stromal cells and 2) genetic ablation of ADAM12-expressing cells decreased tissue fibrosis during scarring. Targeting ADAM12 might represent a new therapeutic approach in inflammatory diseases.
For collaborative research and/or licensing.
Inventors: Philippe Desprès
Invention Disclosure: 2010-025, 2010-027
Key words: emerging disease, human viral disease, recombinant viral antigens, stable cell line, viral serodiagnosis
The present invention relates to a novel enhancer of protein production in host cells. It discloses a vector for expressing recombinant proteins in these cells, comprising a nucleotide sequence encoding i) a secretion peptidic signal, ii) a 6-methylguanine-DNA-methyltransferase enzyme (MGMT, EC 2.1.63), a mutant or a catalytic domain thereof, and iii) a recombinant protein. Said MGMT enzyme is preferably the so-called SNAP protein.
Inventeur : Jean-Jacques Panthier
Déclaration d’invention : 2007-004
Mots clés : anticorps, dermatologie, marqueur, oncologie, vétérinaire
La présente invention concerne une méthode de diagnostic d’un mélanome chez un mammifère, incluant la détection de la surexpression de la protéine RACK1 dans un mélanocyte dudit mammifère et le dépistage d’un mélanome à partir de cette surexpression. L’invention vise également à déterminer le stade tumoral d’un mélanocyte d’un mammifère en détectant la surexpression de la protéine RACK1 dans le mélanocyte, ainsi que le stade tumoral de la cellule à partir de cette surexpression.
Inventors: Frédéric Tangy
Invention Disclosure: 2002-020
Key words: recombinant, measle-based vaccine, chimeric, Flu, influenza, RSV
A replicating viral vector derived from measles vaccine, one of the safest human live-attenuated vaccines. Constructed from the genomic cDNA of the Schwarz strain of measles virus, this RNA vector is able to express very stably as much as 5 kb of additional genes, either cytoplasmic or membrane proteins.
The new vaccine candidates generated from this vector are intended to be used either in naïve children to simultaneously protect from measles and immunize against other viral antigens (such as HIV, Dengue, malaria…), or in adults as a booster of pre-existing immunity to measles.
Inventors: Marie-Louise Michel
Invention Disclosure: 2007-36
Key words: recombinant, HBV, Hepatitis B, therapeutic vaccine
400 million of people are chronically infected with HBV and more than 1 million die each year from HBV-related liver cirrhosis and hepatocellular carcinoma.
We designed a recombinant HBV vector, derived from the HBV genome, that will express and present foreign antigenic epitopes (derived from common pathogens like flu for instance) at the surface of HBV-infected hepatocytes.
Thus, these epitopes will serve as targets for the T-cells of the immune system which will destroy the HBV-infected cells only.
Inventors: Spencer Shorte
Invention Disclosure: 2010-005
Key words: medical imaging, optical imaging, bioluminescence, FUEL
(Fluorescence by Unbound Excitation from Luminescence), enhancement, near-infrared
A unique enhanced optical imaging technique based on Bioluminescence Resonance Energy Transfer (BRET) which can be employed to innovative in vivo/in vitro applications in tissue diagnosis, non-invasive detection of bacterial infection, monitoring on small animals and multimodal medical imaging.
For collaborative research and/or licensing.
Inventors: Monique Lafon
Invention Disclosure: 2008-88 and 2011-20
Key words: Peptide, Neuroregeneration, Neurite Outgrowth, Axon Regeneration, Neuroprotection, Regenerative Medicine, Nerve and Spinal Cord Injuries, SCI, ALS, Neurodegenerative Diseases
New neuroprotective intracellular peptides from viral origin with spectacular neuroprotective and neuroregenerative properties. They specifically activate neurosurvival pathways in damaged nerves and degenerating neurons. Mechanism of action, targets and molecular signature of the biomolecules have been described in details. A proof of concept of efficacy in damaged axons has been obtained in vitro, and the capacity in repairing injured nerves has also been obtained in rat model of peripheral sensory nerve injury. Optimization of a delivery system able to cross blood brain barrier or blood nerve barrier and, to target neurons specifically is now in process. These peptides have also promising potential for restoring or prolonging neuronal plasticity in a large set of neurodegenerative diseases.
Inventors: Caroline Demangel
Invention Disclosure: 2010-15 and 2011-25
Key words: Key words: Molecule, Pain, Inflammation, Autoimmune Disorders
Mycolactone is an original macrolide produced by Mycobacterium ulcerans that blocks the production of chemotactic signals by dendritic cells, suppresses the release of cytokines by macrophages and lymphocytes, and severely impairs T cell homing properties in the mouse model. Patients infected with M. ulcerans, show cellular responses defects at both the local and systemic levels. Cutaneous lesions are painless. This strongly suggests that Mycolactone may also have analgesic properties, possibly dependent on its immunomodulatory effects. Structural variants of natural Mycolactone have been synthesized and retained selectively the immuno-modulatory properties in bioassays. Actually, in vivo assays to evaluate analgesic properties of these variants are in progress.